Haemonetics Corp. v. Baxter Healthcare Corp.

517 F. Supp. 2d 514, 2007 U.S. Dist. LEXIS 72512, 2007 WL 2800797
CourtDistrict Court, D. Massachusetts
DecidedAugust 16, 2007
DocketCivil Action 05-12572-NMG
StatusPublished
Cited by3 cases

This text of 517 F. Supp. 2d 514 (Haemonetics Corp. v. Baxter Healthcare Corp.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Haemonetics Corp. v. Baxter Healthcare Corp., 517 F. Supp. 2d 514, 2007 U.S. Dist. LEXIS 72512, 2007 WL 2800797 (D. Mass. 2007).

Opinion

MEMORANDUM & ORDER

NATHANIEL M. GORTON, District Judge.

The plaintiff, Haemonetics Corporation (“Haemonetics”) alleges infringement of United States Patent No. 6,705,983 (“the '983 patent”) by defendants, Baxter Healthcare Corporation and Baxter International Inc. (collectively, “Baxter”) and Fenwal, Inc. (“Fenwal”). 1 The '983 patent *515 describes a method and apparatus for the separation and collection of blood components through a continuous centrifugal system. On July 13, 2007, the Court held a Markman hearing at which the parties offered arguments in support of their respective claim construction briefs regarding the disputed terms. The following is the Court’s ruling with respect to those terms.

I. Background

The patent at issue involves a process known as centrifugation. In brief, centrifugation involves the placement of a fluid sample (e.g. blood) within a container or vessel which is then rotated at high speed, exerting a centrifugal force on the fluid. That force, a gravity-like pull, separates the fluid’s components based on their different densities and rates of settling. The result is a series of separate layers radiating from the center that corresponds to the different densities of the fluid’s components.

Since the 1970s, new developments have supplemented this basic centrifugation process and enabled continuous centrifuges. Continuous centrifuges allow for the addition and withdrawal of materials from the vessel while the device is in operation. A rubber tube, containing numerous smaller channels, connects the spinning vessel with a non-rotating support structure, forming a question mark shape around the vessel. The tube permits the transportation of particular components in and out of the centrifugal container. Because the vessel is rotating at a rate of two to, the rubber tube also needs to spin in order to prevent twisting and breakage. The rubber tube passes through an aperture outside of the vessel which is connected to a shaft rotating at a rate of one co, half the speed of the vessel.

Jean-Denis Roehat, a Swiss engineer, developed a system whereby a blood separation device utilizes this continuous centrifuge process to remove blood from a donor, extract the desired components and return the remainder to the donor in a continuous flow. While neither the continuous centrifuge process nor the one w: two w ratio concept was new, its application to blood donation (apheresis) using a small, lightweight and disposable method was developed by Roehat and is the subject of the patent. The patent’s specific contribution to the field is the particularly small diameter and height of the vessel and tubing which minimizes the size and weight of the device and balances the stresses placed on the tubing.

The '983 patent has a total of 22 claims. In this pending suit, there are only two groups of claims at issue: 1) independent Claim 1 and its dependent Claims 2-7 and 9 and 2) independent Claim 16 and its dependent Claims 17-19.

The application for the patent was first filed in the European Patent Office on April 9, 1999. It was then subsequently filed as an international Patent Cooperation Treaty (“PCT”) application on April 7, 2000. In order to bring the claims into conformity with the United States Patent Office practice, the PCT application was first translated from the original French into English. During the amendment process, various changes were made to clarify the terminology and respond to objections. The claims were then amended again into their present form as Claims 1-22. On March 16, 2004, patent number 6,705,983 was issued by the United States Patent Office.

Haemonetics asserts that in or about 2003, Baxter began offering and selling a *516 blood component collection system known as the Alyx System which includes a centrifugal device.

II. Analysis

A. Legal Standard

In analyzing a patent infringement case, a Court must 1) determine the meaning and scope of the patent claims asserted to be infringed and 2) compare the properly construed claims to the infringing device. Markman v. Westview Instruments, Inc., 52 F.3d 967, 976 (Fed.Cir.l995)(en banc), aff'd, 517 U.S. 370, 116 S.Ct. 1384, 134 L.Ed.2d 577 (1996). The first step, known as claim construction, is an issue of law for the court to decide, while the second step is determined by the finder of fact. Id. at 979.

Courts are to give claim terms “their ordinary and customary meaning.” Phillips v. AWH Corp., 415 F.3d 1303, 1312 (Fed.Cir.2005)(en. banc)(quoting Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576, 1582 (Fed.Cir.1996)). The Court’s responsibility is to determine the meaning of claim terms as they would be understood by persons of ordinary skill in the relevant art. Bell Atlantic Network Serv., Inc. v. Covad Comm. Group, Inc., 262 F.3d 1258, 1267 (Fed.Cir.2001). Where the ordinary meaning of a claim is not apparent, there is a hierarchy of sources to aid in the court’s claim construction: 1) intrinsic evidence (i.e., the words themselves, specification and prosecution history) and 2) extrinsic evidence (e.g., dictionaries and treatises). Phillips, 415 F.3d at 1313-14. While extrinsic evidence may be useful in construing claims, the intrinsic evidence should be afforded the greatest weight in determining what a person of ordinary skill would have understood a claim to mean. The Federal Circuit urges caution in the use of extrinsic evidence. Id. at 1319-24.

Among the sources of intrinsic evidence, the claims and specifications themselves are most important. The particular context in which a term is used in the asserted claim and the use of the term in other claims can be “highly instructive”. Id. at 1314. Granted, of course, the claims “do not stand alone” and “must be read in view of the specification of which they are a part”. Id. at 1315 (quoting Markman, 52 F.3d at 978). Not surprisingly, it is, therefore, the specification that is “the single best guide to the meaning of a disputed term”. Id. at 1303.

B. Disputed Terms

1. Claims 1-7, 9

With respect to claims 1-7 and 9, the parties have only one minor dispute involving the term “drive units”, specifically the “first drive units” and the “second drive units”. The parties agree that they refer to an “assemblage of components responsible for rotation” at a rate of one w and two co, respectively.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Chevron U.S.A. Inc. v. University of Wyoming Research
978 F.3d 1361 (Federal Circuit, 2020)
Haemonetics Corp. v. Baxter Healthcare Corp.
607 F.3d 776 (Federal Circuit, 2010)
Haemonetics Corp. v. Baxter Healthcare Corp.
577 F. Supp. 2d 482 (D. Massachusetts, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
517 F. Supp. 2d 514, 2007 U.S. Dist. LEXIS 72512, 2007 WL 2800797, Counsel Stack Legal Research, https://law.counselstack.com/opinion/haemonetics-corp-v-baxter-healthcare-corp-mad-2007.